Cagrilintide Reference Overview

Compound Reference Overview

Field Value
Name Cagrilintide
Reference Code CAGRI
Category Long-Acting Amylin Analog (Investigational)
Example Strength 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg (clinical trial doses; investigational)
Reference Range 0.25 mg – 2.4 mg once weekly (evaluated in Phase 2/3 clinical programs)
Frequency Once weekly (clinical trial reference)
Key Safety Warning Investigational Status: Cagrilintide is not FDA approved. As an amylin analog, it slows gastric emptying and may increase gastrointestinal adverse events. Use caution in patients with severe gastrointestinal motility disorders (e.g., gastroparesis).

Mechanism of Action (Educational)

Cagrilintide is a long-acting analog of amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. It activates amylin receptors in the area postrema and other central appetite-regulating regions of the brain.

Amylin receptor activation is associated with delayed gastric emptying, increased satiety, reduced caloric intake, and suppression of postprandial glucagon secretion. These mechanisms form the basis for its investigation in obesity and metabolic disease, including combination programs with GLP-1 receptor agonists (e.g., CagriSema).

Indications (Investigational)

  • Obesity (Phase 2 and Phase 3 development)
  • Type 2 diabetes mellitus (clinical development)
  • Combination therapy with semaglutide (CagriSema programs)

Administration (Clinical Trial Reference)

Parameter Details
Route Subcutaneous
Frequency Once weekly
Injection Sites Abdomen, thigh, or upper arm (rotate sites)
Timing Administered on the same day each week

Pharmacokinetics (Clinical Trial Data)

Cagrilintide demonstrates a prolonged duration of action consistent with once-weekly administration. Clinical trial materials report an approximate half-life of ~6–8 days, supporting weekly dosing schedules.

Steady-state concentrations are achieved after several weeks of administration. Metabolism occurs through peptide degradation pathways similar to other therapeutic peptides.

Titration Schedule (Clinical Trial Reference)

The following escalation reflects dosing strategies evaluated in investigational programs and is provided for literature reference only.

  • Weeks 1–4: 0.25 mg once weekly
  • Weeks 5–8: 0.5 mg once weekly
  • Weeks 9–12: 1.0 mg once weekly
  • Weeks 13–16: 1.7 mg once weekly
  • Week 17+: 2.4 mg once weekly

Gradual escalation is recommended to improve gastrointestinal tolerability. Slower titration may reduce the incidence and severity of nausea and vomiting.

Reconstitution & Concentration (Mathematical Standardization Model)

For educational standardization purposes, concentration may be normalized so that 0.10 mL (10 insulin units) = 0.25 mg. This supports clean unit-to-milligram conversion across the investigational escalation steps.

Parameter Value
Target Concentration 2.5 mg/mL
Unit Conversion 0.10 mL (10 units) = 0.25 mg
Example (10 mg vial) Reconstitute with 4.0 mL bacteriostatic water → 2.5 mg/mL
Stability Up to 28 days refrigerated (varies by formulation and compounding standards)

Conversion Reference

  • 10 units = 0.25 mg
  • 20 units = 0.5 mg
  • 40 units = 1.0 mg
  • 68 units = 1.7 mg
  • 96 units = 2.4 mg

This section is provided strictly for arithmetic illustration and does not constitute dosing guidance. Investigational or future commercial presentations may differ in preparation and handling requirements.

Safety & Contraindications (Summary)

Contraindications

  • Known hypersensitivity to cagrilintide or formulation components
  • Pregnancy or breastfeeding

Relative Cautions

  • Severe gastrointestinal motility disorders (e.g., gastroparesis)
  • Concomitant insulin therapy (monitor for hypoglycemia)

Adverse Events

  • Nausea (dose-dependent)
  • Vomiting
  • Diarrhea
  • Injection site reactions
  • Reduced appetite

Serious Adverse Events

  • Severe gastrointestinal intolerance
  • Dehydration secondary to persistent vomiting

Drug Interactions

  • Concomitant insulin or sulfonylureas may increase hypoglycemia risk
  • Delayed gastric emptying may alter absorption of certain oral medications

Monitoring (Clinical Trial Based)

  • Fasting glucose and HbA1c (if used in diabetes populations)
  • Body weight and appetite changes
  • Gastrointestinal symptoms and hydration status
  • Tolerability during dose escalation

Mathematical Calculation Tool

The calculator below allows mathematical concentration and volume calculations using variable vial strengths and reconstitution volumes. This tool is provided strictly for arithmetic reference.

Peptide Reconstitution Calculator

For Educational & Professional Reference Only

⚠️ This is a mathematical reference tool only. No medical or dosing advice is provided.

Disclaimer

Cagrilintide is an investigational compound that is not FDA approved. This content is provided strictly as a pharmacologic and mathematical reference for educational and professional purposes. It does not constitute medical advice, prescribing guidance, diagnosis, or treatment recommendations. All clinical decisions must be made by a licensed healthcare professional in accordance with applicable regulations.

Reference Sources